Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EPS (Weighted Average and Diluted) (2023 - 2026)

Contineum Therapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.39 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 37.1% to -$0.39 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.98 through Mar 2026, changed 0.0% year-over-year, with the annual reading at -$2.17 for FY2025, 0.46% changed from the prior year.
  • EPS (Weighted Average and Diluted) came in at -$0.39 for Q1 2026, up from -$0.55 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.84 in Q2 2023 to a low of -$2.69 in Q3 2023.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.4 (2024), against an average of -$0.57.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 85.13% in 2024 against a maximum downside of 146.43% in 2024.
  • Contineum Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.35 in 2023, then tumbled by 62.86% to -$0.57 in 2024, then increased by 4.34% to -$0.55 in 2025, then rose by 28.48% to -$0.39 in 2026.
  • Per Business Quant, the three most recent readings for CTNM's EPS (Weighted Average and Diluted) are -$0.39 (Q1 2026), -$0.55 (Q4 2025), and -$0.62 (Q1 2025).